Novartis AG ADR (NVS)vsPhreesia Inc (PHR)
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
PHR
Phreesia Inc
$12.62
-1.48%
HEALTHCARE · Cap: $795.13M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 11197% more annual revenue ($57.36B vs $507.79M). NVS leads profitability with a 17.5% profit margin vs 2.1%. NVS trades at a lower P/E of 30.7x. PHR earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold48
out of 100
Grade: D+
PHR
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Margin of Safety
+71.1%
Fair Value
$43.30
Current Price
$12.62
$30.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Earnings expanding 200.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Smaller company, higher risk/reward
ROE of 2.8% — below average capital efficiency
2.1% margin — thin
Operating margin of 4.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : PHR
The strongest argument for PHR centers on EPS Growth, Debt/Equity, Price/Book. Revenue growth of 10.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : PHR
The primary concerns for PHR are Market Cap, Return on Equity, Profit Margin. A P/E of 75.3x leaves little room for execution misses. Thin 2.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
PHR carries more volatility with a beta of 0.72 — expect wider price swings.
PHR is growing revenue faster at 10.4% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PHR scores higher overall (49/100 vs 48/100) and 10.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Phreesia Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Phreesia, Inc. provides integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?